HANGZHOU, China – July 16, 2025 –HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that the first patient has been dosed in its Phase 1 trial of HF50 to treat patients with HER2 high and HER2 low advanced solid tumors.

The Phase 1 open label, dose escalation trial in China will assess safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy. It will also establish a recommended dose for the Phase 2 trial. Details of the study design and contacts are on ClinicalTrials.gov (NCT06822998).

HighField CEO and Scientific Founder Yuhong Xu, Ph.D., said, “HF50 is a new type of cancer therapeutics designed to use a lipid bilayer and physical forces to link antibody binding domains and payloads.”

Dr. Xu added, “HF50’s advantages over bispecific antibodies and CAR T cells involve its integration of multiple functions. One is to activate T cells in a controllable way and facilitate their interaction with cancer cells. The other is to carry payload to turn immunologically ‘cold’ tumors ‘hot’ for higher anti-tumor efficacy.

About HighField Biopharmaceuticals

Highfield is a clinical stage company focused on novel applications of liposome constructs directed to immuno-oncology and gene therapy.  HighField’s lead products in clinical trials are K1, derived from its ADCplex^TM platform, folloed by HF50, derived from its TCEplex^TM platform. The company’s pipeline also includes K16, a drug encapsulated immune modulating liposome targeting myeloid-derived suppressor cells in clinical trials for refractory cancers; and HFG1, derived from its tLNPplex™ platform, for mRNA expression of a GLP-1R agonist for weight loss and diabetes. For more information visit https://highfieldbio.com

Media Contact:
Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net

425-306-8716